<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957437</url>
  </required_header>
  <id_info>
    <org_study_id>D3190C00016</org_study_id>
    <nct_id>NCT00957437</nct_id>
  </id_info>
  <brief_title>Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305</brief_title>
  <official_title>A Phase I, Randomised, Open, Single-centre Study to Evaluate the Pharmacokinetics of Different Extended-release Formulations of AZD1305 When Given as Single and Repeated Oral Doses to Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics of different extended-release
      formulations of AZD1305 when given as single and multiple oral doses to healthy male
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic variables of AZD1305 by assessment of drug concentrations in plasma</measure>
    <time_frame>From predose until 48 hours post last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events, ECG variables, vital signs, physical examination, laboratory variables and weight</measure>
    <time_frame>Frequent safety measurements during the study, from screening period to follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: 3 way crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1305: ER test formulation 1 (w/wo food) and reference formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B1: single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1305: ER test formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B2: 3 way crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1305: ER test formulation 2 (w/wo food) and reference formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1305</intervention_name>
    <description>Single Oral Dose, ER formulation 1</description>
    <arm_group_label>Part A: 3 way crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1305</intervention_name>
    <description>ER formulation 1, bid for 5 days</description>
    <arm_group_label>Part B1: single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1305</intervention_name>
    <description>Single Oral Dose, ER formulation 2</description>
    <arm_group_label>Part B2: 3 way crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed, written and dated informed consent prior to any study specific
             procedures.

          -  Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more
             than 100 kg.

        Exclusion Criteria:

          -  History or presence of any clinically significant disease or disorder in the opinion
             of the investigator.

          -  Use of nicotine in the last 4 weeks before screening and not more than 7 cigarettes
             per week (equivalent to 1 nicotine patch or 7 nicotine gums per week) before then.
             There will be no smoking until follow-up visit.

          -  Any clinically relevant abnormal findings in physical examination, clinical chemistry,
             haematology, urinalysis, vital signs or ECG at baseline in the opinion of the
             investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Lunde</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D MÃ¶lndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Francke</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit, London UK.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <last_update_submitted>November 25, 2009</last_update_submitted>
  <last_update_submitted_qc>November 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>male</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>AZD1305</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

